Department for Innovation in Biological, Agrofood and Forest Systems, University of Tuscia, Viterbo, Italy.
Department for Innovation in Biological, Agrofood and Forest Systems, University of Tuscia, Viterbo, Italy; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, 55455, USA.
Dev Comp Immunol. 2019 Jul;96:9-17. doi: 10.1016/j.dci.2019.02.012. Epub 2019 Feb 18.
The increasing resistance to conventional antibiotics is an urgent problem that can be addressed by the discovery of new antimicrobial drugs such as antimicrobial peptides (AMPs). AMPs are components of innate immune system of eukaryotes and are not prone to the conventional mechanisms that are responsible of drug resistance. Fish are an important source of AMPs and, recently, we have isolated and characterized a new 22 amino acid residues peptide, the chionodracine (Cnd), from the Antarctic icefish Chionodraco hamatus. In this paper we focused on a new Cnd-derived mutant peptide, namely Cnd-m3a, designed to improve the selectivity against prokaryotic cells and the antimicrobial activity against human pathogens of the initial Cnd template. Cnd-m3a was used for immunization of rabbits, which gave rise to a polyclonal antibody able to detect the peptide. The interaction kinetic of Cnd-m3a with the Antarctic bacterium Psychrobacter sp. (TAD1) was imaged using a transmission electron microscopy (TEM) immunogold method. Initially the peptide was associated with the plasma membrane, but after 180 min of incubation, it was found in the cytoplasm interacting with a DNA target inside the bacterial cells. Using fluorescent probes we showed that the newly designed mutant can create pores in the outer membrane of the bacteria E. coli and Psychrobacter sp. (TAD1), confirming the results of TEM analysis. Moreover, in vitro assays demonstrated that Cnd-m3a is able to bind lipid vesicles of different compositions with a preference toward negatively charged ones, which mimics the prokaryotic cell. The Cnd-m3a peptide showed quite low hemolytic activity and weak cytotoxic effect against human primary and tumor cell lines, but high antimicrobial activity against selected Gram - human pathogens. These results highlighted the high potential of the Cnd-m3a peptide as a starting point for developing a new human therapeutic agent.
越来越多的抗生素耐药性是一个紧迫的问题,可以通过发现新的抗菌药物来解决,如抗菌肽(AMPs)。AMPs 是真核生物先天免疫系统的组成部分,不容易受到导致耐药性的传统机制的影响。鱼类是 AMPs 的重要来源,最近,我们从南极冰鱼 Chionodraco hamatus 中分离并鉴定了一种新的 22 个氨基酸残基的肽,即 chionodracine(Cnd)。在本文中,我们专注于一种新的 Cnd 衍生突变肽,即 Cnd-m3a,旨在提高对原核细胞的选择性和对人类病原体的抗菌活性。Cnd-m3a 用于免疫兔子,产生了一种能够检测该肽的多克隆抗体。使用透射电子显微镜(TEM)免疫金方法对 Cnd-m3a 与南极细菌 Psychrobacter sp.(TAD1)的相互作用动力学进行了成像。最初,该肽与质膜结合,但在孵育 180 分钟后,发现其在细胞质中与细菌细胞内的 DNA 靶标相互作用。使用荧光探针,我们表明新设计的突变体能在大肠杆菌和 Psychrobacter sp.(TAD1)的外膜上形成孔,证实了 TEM 分析的结果。此外,体外试验表明,Cnd-m3a 能够结合不同组成的脂质体,对带负电荷的脂质体有偏好,这模拟了原核细胞。Cnd-m3a 肽的溶血活性较低,对人原代和肿瘤细胞系的细胞毒性较弱,但对选定的革兰氏阴性人类病原体具有较高的抗菌活性。这些结果突出了 Cnd-m3a 肽作为开发新型人类治疗剂的起点的巨大潜力。